23 results
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an “affirmative defense” in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.
A Trading Plan must either (1
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
litigation against the issuer of such securities. If any of the holders of ADSs were to bring such a lawsuit against us, we could incur substantial costs … defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination
424B5
pt30wto6 gj7hiuom9f
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
md2 3mmztvs9f
9 Feb 21
Prospectus supplement for primary offering
5:24pm
424B5
qvic0taatwx 4fdk
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
7oapj2ovclpmnh k80
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-10.1
d0s d6gx1dsg
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
qfshxwqjcb3q3kp89 zo
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
p93y p39ysgwanzgin
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-10.1
8r4vygkgjox
3 Sep 19
Current report (foreign)
4:05pm
20-F
vakorbg3jdzs jo
29 Apr 19
Annual report (foreign)
4:59pm
424B3
foabi8fqm nc
20 Mar 19
Prospectus supplement
4:58pm